Investing.com -- Raymond James has initiated coverage on Super Micro Computer (NASDAQ:SMCI) with an Outperform rating and a $41 price target, highlighting the company’s strong position in AI ...

Echoing comments from his counterpart at Stifel, Raymond James CEO Paul Shoukry said Wednesday he doesn't think the turmoil now roiling markets will weigh on his firm's recruitment efforts.

Raymond James is offering its independent advisors a deal: If they need cash to invest in technology, hire staff or buy another firm, they can raise it by selling part of their practice to Raymond ...

Raymond James is reinforcing its appeal as a destination for independent advisors with a new advisory practice financing option. The firm's equity financing option, unveiled Monday, is designed to ...

Supermicro shares surged Tuesday after Raymond James initiated coverage of the company with a bullish rating. The AI server maker has "emerged as a market leader," the analysts said. Even with ...

Raymond James & Associates Inc. successfully hosted its Inaugural Micronesia Investment and Retirement Plans Conference for its clients in the region, bringing together a distinguished lineup of ...

Raymond James has expanded its independent advisor network with the addition of two financial professionals who were previously affiliated with Edward Jones, strengthening its presence in the ...

Investing.com -- Raymond James downgraded Apellis Pharmaceuticals (NASDAQ:APLS) to Outperform from Strong Buy following a first-quarter sales miss and rising concerns over volatility in the company’s ...

Raymond James Financial reported adjusted quarterly earnings per share of $2.42 for the period ending March 31, missing analyst estimates of $2.45. Raymond James reported adjusted earnings of $2. ...

On Friday, Raymond James made a significant adjustment to Cable One’s stock rating, moving it from "Outperform" to "Market Perform." The decision came in response to the company’s sudden ...

Fintel reports that on May 9, 2025, Raymond James downgraded their outlook for Apellis Pharmaceuticals (BIT:1APLS) from Strong Buy to Outperform. There are 533 funds or institutions reporting ...